Description

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm (NODE-1)

The primary objective of this study is to demonstrate the superiority of at least one dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Contact

Stephen Harold harold@bcm.eduPhone 1: (832) 355-3710
IRB: h-37092

Status

Active

Created

Oct 17, 2016